In a filing, Vor Biopharma Inc revealed its 10% Owner Reprogrammed Interchange LLC unloaded Company’s shares for reported $0.66 million on Sep 15 ’25. In the deal valued at $1.64 per share,400,000 shares were sold. As a result of this transaction, Reprogrammed Interchange LLC now holds 33,228,487 shares worth roughly $53.17 million.
Then, Reprogrammed Interchange LLC sold 300,000 shares, generating $526,230 in total proceeds. Upon selling the shares at $1.75, the 10% Owner now owns 33,628,487 shares.
Before that, Reprogrammed Interchange LLC sold 284,805 shares. Vor Biopharma Inc shares valued at $521,421 were divested by the 10% Owner at a price of $1.83 per share. As a result of the transaction, Reprogrammed Interchange LLC now holds 33,928,487 shares, worth roughly $54.29 million.
H.C. Wainwright upgraded its Vor Biopharma Inc [VOR] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. Goldman began covering VOR with “Neutral” recommendation on April 27, 2022. H.C. Wainwright started covering the stock on December 17, 2021. It rated VOR as “a Buy”.
Price Performance Review of VOR
On Monday, Vor Biopharma Inc [NASDAQ:VOR] saw its stock fall -8.05% to $1.6. Over the last five days, the stock has lost -19.19%. Vor Biopharma Inc shares have risen nearly 50.94% since the year began. Nevertheless, the stocks have risen 44.14% over the past one year.
How much short interest is there in Vor Biopharma Inc?
A steep rise in short interest was recorded in Vor Biopharma Inc stocks on 2025-08-29, growing by 1.21 million shares to a total of 19.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 18.57 million shares. There was a rise of 6.13%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 03, 2021 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $38 price target.
